Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Farrerol SCHEMBL928045 | 0.87 | ESR1 (0.71) | ESR1ESR2POLBMEN1KMT2A | |
| Farrerol SCHEMBL28048308 | 0.87 | ESR1 (0.71) | ESR1ESR2POLBMEN1KMT2A | |
| SCHEMBL11120379 | 0.85 | ESR1 (0.57) | ESR1ESR2POLBMEN1KMT2A | |
| Demethoxymatteucinol SCHEMBL29204370 | 0.84 | ABCG2 (0.64) | ESR1ESR2POLBMEN1KMT2A | |
| Demethoxymatteucinol SCHEMBL664144 | 0.84 | ABCG2 (0.64) | ESR1ESR2POLBMEN1KMT2A | |
| SCHEMBL7543177 | 0.82 | CYP1A1 (0.57) | ESR1ESR2POLBMEN1KMT2A | |
| SCHEMBL29776987 | 0.82 | CYP1A1 (0.57) | ESR1ESR2POLBMEN1KMT2A | |
| SCHEMBL1201860 | 0.82 | ESR1 (0.55) | ESR1ESR2POLBMEN1KMT2A | |
| Cyrtominetin SCHEMBL30846161 | 0.81 | POLB (0.62) | ESR1ESR2POLBMEN1KMT2A | |
| Cyrtominetin SCHEMBL1201687 | 0.81 | POLB (0.62) | ESR1ESR2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294374-A1 | FLAVONE/FLAVANONE DERIVATIVES FOR THE SYSTEMIC TREATMENT AND PROPHYLAXIS OF UV-INDUCED DERMATOSES | Krutmann, Jean (DE) | 2003-03-26 | — | — | EP | claimed |
| WO-2002000214-A1 | FLAVONE/FLAVANONE DERIVATIVES FOR THE SYSTEMIC TREATMENT AND PROPHYLAXIS OF UV-INDUCED DERMATOSES | KRUTMANN JEAN (DE) | 2002-01-03 | — | — | WO | claimed |
| EP-2120924-B1 | AN ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-20120251643-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20110045108-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2011-02-24 | — | — | US | disclosed |
| EP-2120924-A2 | AN ANTI-DIABETIC EXTRACT OF HONEYBUSH | Zadec APS (DK) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008110552-A9 | AN ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008110552-A2 | AN ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2008-09-18 | — | — | WO | disclosed |
| US-20040038914-A1 | Flavone/ flavanone derivatives for the systemic treatment and prophlaxis of uv-induced dermatoses | KRUTMANN JEAN (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1294374-A1 | FLAVONE/FLAVANONE DERIVATIVES FOR THE SYSTEMIC TREATMENT AND PROPHYLAXIS OF UV-INDUCED DERMATOSES | Krutmann, Jean (DE) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000214-A1 | FLAVONE/FLAVANONE DERIVATIVES FOR THE SYSTEMIC TREATMENT AND PROPHYLAXIS OF UV-INDUCED DERMATOSES | KRUTMANN JEAN (DE) | 2002-01-03 | — | — | WO | disclosed |
| US-4636569-A | Pharmaceutical compositions containing compounds with a flavanone skeleton, process for the preparation of the said compound and novel compounds obtained | INVERNI DELLA BEFFA S.P.A. (IT) | 1987-01-13 | — | — | US | disclosed |
| EP-0122053-A2 | Pharmaceutical compositions containing compounds with a flavanone skeleton and process for the preparation of said compounds | INVERNI DELLA BEFFA S.P.A. (IT) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045108-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | IAPP, DPP4, DPP3 | ESR1 4740/4885ESR2 3956/4885POLB 2892/4885 |
| US-20120251643-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | IAPP, DPP4, DPP3 | ESR1 4740/4885ESR2 3956/4885POLB 2892/4885 |
| US-20040038914-A1 | Flavone/ flavanone derivatives for the systemic treatment and prophlaxis of uv-induced dermatoses | COLGALT1, PNN, F2 | ESR1 712/4885ESR2 1367/4885POLB 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.